Hims & Hers Adds Biomarker Tracking, Acquires YourBio Health to Boost Platform
Hims & Hers launched Labs for longitudinal biomarker tracking and invested in AI-driven diagnostics and care orchestration to deepen personalization across its digital healthcare platform. The company also acquired YourBio Health’s patented pain-free blood sampling technology while its shares have fallen 44.8% over the past year with a 1.9x forward P/S ratio.
1. Platform Enhancements
Hims & Hers has expanded its proprietary digital ecosystem by launching Labs, enabling longitudinal biomarker tracking integrated into personalized provider action plans. The company is scaling its AI and platform infrastructure to enhance diagnostics, treatment matching and care orchestration, positioning software and data feedback loops as core differentiators.
2. Strategic Acquisition
The recent purchase of YourBio Health brings in patented, pain-free blood sampling technology, allowing tighter integration between at-home diagnostics and Hims & Hers’s digital care delivery. This acquisition is intended to accelerate product innovation and reinforce the company’s vertically integrated healthcare model.
3. Financial Performance and Valuation
Shares of Hims & Hers have declined 44.8% over the past year, underperforming the industry’s 35.1% drop. The stock trades at a forward 12-month price-to-sales multiple of 1.9x versus an industry average of 3.7x, reflecting market caution despite a projected 85.2% EPS improvement for 2025.